MX368407B - Tratamiento de cancer prostatico con inhibidores de tor cinasa. - Google Patents

Tratamiento de cancer prostatico con inhibidores de tor cinasa.

Info

Publication number
MX368407B
MX368407B MX2015004874A MX2015004874A MX368407B MX 368407 B MX368407 B MX 368407B MX 2015004874 A MX2015004874 A MX 2015004874A MX 2015004874 A MX2015004874 A MX 2015004874A MX 368407 B MX368407 B MX 368407B
Authority
MX
Mexico
Prior art keywords
prostate cancer
treatment
tor kinase
kinase inhibitors
tor
Prior art date
Application number
MX2015004874A
Other languages
English (en)
Other versions
MX2015004874A (es
Inventor
Mortensen Deborah
K Narla Rama
Mae Hege Kristen
Raymon Heather
Elizabeth Fultz Kimberly
Tsuji Toshina
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of MX2015004874A publication Critical patent/MX2015004874A/es
Publication of MX368407B publication Critical patent/MX368407B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proporcionan los métodos para tratar o prevenir cáncer de próstata, que consisten en administrar una cantidad eficaz de un inhibidor de TOR cinasa a un paciente que tenga cáncer de próstata.
MX2015004874A 2012-10-18 2013-10-17 Tratamiento de cancer prostatico con inhibidores de tor cinasa. MX368407B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261715510P 2012-10-18 2012-10-18
PCT/US2013/065363 WO2014062878A2 (en) 2012-10-18 2013-10-17 Treatment of cancer with tor kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2015004874A MX2015004874A (es) 2015-08-05
MX368407B true MX368407B (es) 2019-10-02

Family

ID=50023830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004874A MX368407B (es) 2012-10-18 2013-10-17 Tratamiento de cancer prostatico con inhibidores de tor cinasa.

Country Status (19)

Country Link
US (1) US20140113904A1 (es)
EP (1) EP2908814B1 (es)
JP (3) JP2015534981A (es)
KR (2) KR102157914B1 (es)
CN (2) CN105050601A (es)
AU (1) AU2013202768B2 (es)
BR (1) BR112015008834A2 (es)
CA (1) CA2888609C (es)
EA (1) EA029164B1 (es)
ES (1) ES2777936T3 (es)
IL (1) IL238326B (es)
MX (1) MX368407B (es)
MY (1) MY176599A (es)
NI (1) NI201500055A (es)
PH (1) PH12015500867B1 (es)
SG (2) SG11201502999YA (es)
UA (1) UA117000C2 (es)
WO (1) WO2014062878A2 (es)
ZA (1) ZA201503105B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AU2014207641A1 (en) 2013-01-16 2015-08-06 Signal Pharmaceuticals, Llc Substituted Pyrrolopyrimidine Compounds, compositions thereof, and methods of treatment therewith
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
AU2016356694B2 (en) 2015-11-20 2021-07-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
CN110996955A (zh) 2017-06-22 2020-04-10 细胞基因公司 以乙型肝炎病毒感染为特征的肝细胞癌的治疗
CN110403943B (zh) * 2019-08-19 2022-05-17 陕西科技大学 Cc-115在制备抗真菌药物中的应用及其药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1159582C (zh) * 2001-12-08 2004-07-28 云南大学 一种人体全血或血清总前列腺特征性抗原值，总前列腺特征性抗原灰区值检测方法
GB0509748D0 (en) 2005-05-13 2005-06-22 Univ Glasgow Materials and methods relating to cell based therapies
WO2007117653A2 (en) * 2006-04-07 2007-10-18 University Of South Florida Cdk9-pi3k-akt inhibitors for cancer treatment
JP5513118B2 (ja) * 2006-10-19 2014-06-04 シグナル ファーマシューティカルズ，エルエルシー ヘテロアリール化合物、その組成物、及びプロテインキナーゼ阻害剤としてのそれらの使用
ZA200902384B (en) 2006-10-19 2010-07-28 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
WO2010044893A1 (en) * 2008-10-17 2010-04-22 Merck & Co. Combination therapy
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
WO2011053518A1 (en) * 2009-10-26 2011-05-05 Signal Pharmaceuticals, Llc Methods of synthesis and purification of heteroaryl compounds
US20120238562A1 (en) * 2011-03-09 2012-09-20 Cedars-Sinai Medical Center Treatment of cancer by targeting molecules that influence mst1/stk4 signaling

Also Published As

Publication number Publication date
EP2908814B1 (en) 2019-12-25
MY176599A (en) 2020-08-18
CA2888609A1 (en) 2014-04-24
WO2014062878A2 (en) 2014-04-24
PH12015500867A1 (en) 2015-06-22
BR112015008834A2 (pt) 2017-07-04
PH12015500867B1 (en) 2015-06-22
ZA201503105B (en) 2016-11-30
EP2908814A2 (en) 2015-08-26
IL238326B (en) 2018-03-29
IL238326A0 (en) 2015-06-30
WO2014062878A3 (en) 2014-06-26
CN110721186A (zh) 2020-01-24
NI201500055A (es) 2015-09-10
EA029164B1 (ru) 2018-02-28
CN105050601A (zh) 2015-11-11
JP2015534981A (ja) 2015-12-07
JP2021050213A (ja) 2021-04-01
UA117000C2 (uk) 2018-06-11
US20140113904A1 (en) 2014-04-24
EA201590744A1 (ru) 2015-11-30
KR102267927B1 (ko) 2021-06-21
KR20200108923A (ko) 2020-09-21
CA2888609C (en) 2020-12-01
AU2013202768A1 (en) 2014-05-08
KR102157914B1 (ko) 2020-09-18
AU2013202768B2 (en) 2015-11-05
JP7162543B2 (ja) 2022-10-28
KR20150070319A (ko) 2015-06-24
WO2014062878A9 (en) 2014-12-18
SG10201810575WA (en) 2019-01-30
MX2015004874A (es) 2015-08-05
SG11201502999YA (en) 2015-05-28
JP2019081771A (ja) 2019-05-30
ES2777936T3 (es) 2020-08-06

Similar Documents

Publication Publication Date Title
PH12018502234B1 (en) Treatment of cancer with tor kinase inhibitors
PH12014502047A1 (en) Treatment of cancer with tor kinase inhibitors
MX357833B (es) Tratamiento del cancer con inhibidores de tor cinasa.
PH12014502029B1 (en) Treatment of cancer with tor kinase inhibitors
MX2015014591A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
MX2015014596A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer.
PH12014502046A1 (en) Treatment of cancer with tor kinase inhibitors
PH12015500867B1 (en) Treatment of prostate cancer with tor kinase inhibitors
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
EA201491695A1 (ru) Лечение рака ингибиторами tor-киназы

Legal Events

Date Code Title Description
FG Grant or registration